The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

If biotech funding continues to increase this year, Danaher could benefit.

The increase in nationwide vacancy to 23.2% is a reversal from the slight dip to end 2025, according to preliminary CBRE data ...

A high-security federal lab tucked into South San Francisco’s life-sciences hub is suddenly up for grabs, with a price tag ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.